23andMe Upgrades to Higher-Density Array, Offers Detailed Analysis of Rx Response, Disease Risk

With the new platform, the company is hoping to provide greater coverage of drug-metabolizing enzymes and transporters, and analyze additional genes associated with drug response.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.